The Lancet. Neurology · 2010
Revising the definition of Alzheimer's disease: a new lexicon.
Conference ProceedingsПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dubois Bruno, Feldman Howard H, Jacova Claudia, Cummings Jeffrey L, Dekosky Steven T, Barberger-Gateau Pascale, Delacourte André, Frisoni Giovanni, Fox Nick C, Galasko Douglas, Gauthier Serge, Hampel Harald, Jicha Gregory A, Meguro Kenichi, O'Brien John, Pasquier Florence, Robert Philippe, Rossor Martin, Salloway Steven, Sarazin Marie, de Souza Leonardo C, Stern Yaakov, Visser Pieter J, Scheltens Philip
Аннотация
Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.